Titlebook: Entry Inhibitors in HIV Therapy; Jacqueline D. Reeves,Cynthia A. Derdeyn Book 2007 Birkh?user Basel 2007 AIDS.HIV.HIV Therapy.HIV infectio

enamel

書目名稱Entry Inhibitors in HIV Therapy影響因子(影響力)




書目名稱Entry Inhibitors in HIV Therapy影響因子(影響力)學(xué)科排名




書目名稱Entry Inhibitors in HIV Therapy網(wǎng)絡(luò)公開度




書目名稱Entry Inhibitors in HIV Therapy網(wǎng)絡(luò)公開度學(xué)科排名




書目名稱Entry Inhibitors in HIV Therapy被引頻次




書目名稱Entry Inhibitors in HIV Therapy被引頻次學(xué)科排名




書目名稱Entry Inhibitors in HIV Therapy年度引用




書目名稱Entry Inhibitors in HIV Therapy年度引用學(xué)科排名




書目名稱Entry Inhibitors in HIV Therapy讀者反饋




書目名稱Entry Inhibitors in HIV Therapy讀者反饋學(xué)科排名

BLOT

時代

墻壁

CREEK

Inhibitors that target gp120 interactions with coreceptor,ssays on human cell lines as syncytium inducing (SI) or non-syncytium inducing (NSI) [.]. NSI viruses predominate early after transmission, are capable of growth in primary macrophages (macrophage tropism), and fail to grow in most established human T cell lines. SI viruses, by contrast, are found i

半球

半球

Entry inhibition of HIV-1 subtype C isolates, [.]. There is less information on how genetic variability might affect the efficacy of a newer class of anti-retrovirals, the entry or fusion inhibitors. This group comprises a diverse collection of compounds that target both viral and host cell components blocking virus attachment and/or fusion an

PACK

重畫只能放棄

Future clinical prospects for entry inhibitors,once (with the FDA approval of a membrane fusion inhibitor, enfuvirtide, in 2003) has this strategic approach resulted in a commercially available agent. Indeed, for more than 15 years, from 1987 to 2003, all available antiretroviral therapies targeted one of two HW-encoded enzymes, reverse transcri

Obsessed